GreenLight Announces Completion of Merger with Fall Line Endurance Fund
July 24, 2023 09:49 ET
|
GreenLight Biosciences
LEXINGTON, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) (“GreenLight” or the “Company”) today announced the closing of its previously announced...
GreenLight Biosciences Announces Expiration of Tender Offer Period for Outstanding Shares
July 20, 2023 08:06 ET
|
GreenLight Biosciences
LEXINGTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) (“GreenLight” or the “Company”) today announced that it is initiating the final steps in...
GreenLight Biosciences Enters into Definitive Merger Agreement with Consortium Led by Fall Line Endurance Fund for Go-Private Transaction
May 30, 2023 07:01 ET
|
GreenLight Biosciences
LEXINGTON, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) (“GreenLight” or the “Company”) today announced that the Company has entered into a definitive...
GreenLight Biosciences Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 11, 2023 07:00 ET
|
GreenLight Biosciences
BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences, PBC (Nasdaq: GRNA), a biotechnology company dedicated to making RNA products affordable and accessible for human health and...
GreenLight Biosciences Releases Inaugural Sustainability Report
April 12, 2023 06:59 ET
|
GreenLight Biosciences
BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s...
GreenLight Biosciences Holdings Confirms Receipt of Indication of Interest from Fall Line
March 30, 2023 16:05 ET
|
GreenLight Biosciences
BOSTON, March 30, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA) (“GreenLight” or the “Company”), a public benefit corporation striving to deliver on the full potential of RNA to...
GreenLight Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results
March 28, 2023 17:05 ET
|
GreenLight Biosciences
Two agriculture solutions now under regulatory review, pending EPA approval: Calantha™, a solution to protect potatoes, and a separate solution to protect honeybees from Varroa miteUpdated clinical...
GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Human Health R&D Day
March 09, 2023 06:59 ET
|
GreenLight Biosciences
-- Progressing human health pipeline conferring mRNA platform advantages for infectious disease and personalized oncology medicines; pursuing capital efficient strategy targeting unmet medical needs,...
GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Plant Health R&D Day
March 07, 2023 06:59 ET
|
GreenLight Biosciences
BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s...
GreenLight Biosciences to Host R&D Day Series on Plant and Human Health Development Strategy
March 01, 2023 06:24 ET
|
GreenLight Biosciences
BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s...